Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 28 of 53 · 2522 articles
This paper suggests that epithelial barrier structure and function may be altered in very early onset pediatric IBD. That could help researchers study disease mechanisms and eventually guide targeted therapies for...
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.
Dual-energy CT quantification of creeping fat could offer a measurable imaging biomarker that reflects transmural inflammation and fibrosis in Crohn’s disease, potentially improving monitoring beyond mucosal healing.
The study examines real-world activity and sedentary patterns in people with Crohn’s disease compared with matched controls and highlights sitting-time differences that could be modified without formal exercise programs.
The work narrows down which genes are likely influenced by Crohn’s disease–associated regulatory DNA in a specific gut immune cell type, helping researchers prioritize targets and understand disease mechanisms.
People with Crohn’s or ulcerative colitis can rarely develop lung problems related to their disease or its treatments, and this review collates what is known about clinical features and therapies.
This review describes a novel, targeted microbiome approach (phage therapy) aimed at bacteria linked to Crohn’s disease. If effective and proven safe in trials, phage therapy could offer a more precise way to reduce...
A person with Crohn disease on multiple immunosuppressive drugs was reported to have tracheobronchial wall thickening, an extraintestinal finding that could reflect infection or inflammation. This may be relevant for...
This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission,...
Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...
Researchers found that immune cells detect the gut-associated yeast Debaryomyces hansenii via Dectin-1 and Card9, and the yeast was enriched in Crohn’s disease ulcers. That suggests a possible microbial–immune link...
If epithelial cells themselves retain disease-linked programs, that could help explain persistent intestinal abnormalities in Crohn’s disease even during remission and point to new biomarker or therapeutic targets...
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Genetics and genomics. The original article is from msn.com.
Fatigue is a frequent, impactful symptom in Crohn’s disease that often goes unmeasured in clinic visits. Knowing which assessment tools exist can help patients and clinicians recognize and address fatigue.
The work helps bridge genetic association signals and the specific immune cells in the intestine where they may act, offering new candidate genes and a method that can probe rare cell types important to IBD biology.
ILC3s live in the intestine and help regulate barrier function and inflammation, so mapping how genetic variants affect gene regulation in these rare cells helps connect inherited risk signals to plausible biology for...
This profile shows how someone with Crohn’s disease can continue competitive athletic pursuits while managing the condition. It highlights common issues for people with IBD—remission, stress-related flares,...
Mapping 3D genome contacts in rare gut immune cells connects Crohn’s disease genetic risk variants to specific genes and pathways, which can clarify disease mechanisms and guide future drug-target research. The study...
ILC3s are rare but important for gut immunity; linking Crohn’s disease genetic risk to the genes they regulate helps move from statistical association toward biological mechanisms that could explain disease pathways.
This study helps move beyond assigning GWAS risk variants to the nearest gene by mapping 3D promoter contacts in gut-enriched ILC3s, so it uncovers new candidate genes and pathways that could explain Crohn’s and other...
The study helps explain how noncoding genetic variants may influence Crohn’s disease by altering 3D genome interactions in rare gut-associated immune cells (ILC3s), pointing to new genes and pathways that could be...
This research links a specific gut-associated yeast to activation of innate immune pathways (Dectin-1–Card9) that drive inflammatory signaling. For people with Crohn disease, it suggests fungal members of the gut...
Dietary patterns are being studied as therapies for pediatric IBD because they may help induce remission or improve disease control without drugs.
Diet-based therapies like CDED + PEN may help control Crohn’s symptoms and improve nutrition without adding medications. This study suggests some adults can maintain remission and gain nutritional benefits over a year...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
People with moderate-to-severe Crohn’s disease may be interested because the study explores a new, repurposed drug (vorinostat) that targets epigenetic and immune pathways and includes a plan to move responding...
The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...
New drugs in mid-stage trials may expand treatment options for people with moderate to severe Crohn's disease, especially those who have not responded to existing therapies. This trial is measuring clinical remission at...
EEN is being evaluated as a non‑pharmacologic induction therapy in adults with active and complicated Crohn’s disease; results could inform whether EEN helps induce remission, improve nutrition, and impact inflammation...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
People with Crohn’s disease may benefit from research that identifies the specific genes and immune pathways driving inflammation — this study points to over 100 genes in gut ILC3 cells that could explain how genetic...
MSCs are an active research area for IBD because they may reduce harmful immune activity and help heal intestinal tissue. Patients following emerging biologic and cell therapies may want to know how MSCs could fit into...
Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at...
Identifying simple features at diagnosis that predict a disabling 5‑year course could help patients and clinicians plan monitoring and treatment intensity earlier after Crohn’s diagnosis.
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...
The review suggests that allergic-type (type 2) immune pathways may play a meaningful role in some people with Crohn's disease, which could point to new treatment options that target IgE, Th2 cytokines, epithelial...
New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...
High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
AI could help standardize endoscopic and histologic scoring in IBD, speed capsule endoscopy interpretation, and improve lesion detection — changes that might affect monitoring and diagnosis workflows for people with...
This study evaluates a less invasive endoscopic option (needle-knife stricturotomy) for Crohn’s-related anorectal strictures and reports real-world outcomes and factors linked to recurrence — information that can inform...
This study provides region-specific pediatric IBD data from the Philippines, highlighting prevalence of very-early-onset disease, perianal involvement in Crohn's, and factors (diagnostic delay, wasting, pancolitis)...
The report suggests Kono‑S is safe and feasible with shorter hospital stays and fewer ileostomies in this early-adoption cohort, which could matter to patients and surgeons planning ileocecal resection.
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...
